IMUNON INC (IMNN)

Introduction

IMUNON INC is a clinical-stage biotechnology company listed on NASDAQ under the ticker IMNN. The company develops DNA-based and immunology-driven therapies targeting conditions such as cancer and infectious diseases. Its two proprietary platforms—TheraPlas® for anti-cancer nucleic acid therapies and PlaCCine® for nucleic acid vaccines—aim to utilize the body’s immune system through localized expression of therapeutic molecules.

Corporate Structure and Leadership

• Headquarters: Lawrenceville, New Jersey
• Founded: 1982
• Employees: 11–50 (LinkedIn)
• Senior Management: Over 50 years of combined experience in research, innovation, and capital management
• Key Platforms and Partnerships:
  • Collaborations with leading research institutions
  • Pipeline projects targeting markets worth billions of dollars

Recent Developments and News

Clinical and Scientific Milestones

• Phase 2 OVATION 2 Data
  IMUNON announced new data from its Phase 2 OVATION 2 study in advanced ovarian cancer, supporting the TheraPlas® platform’s local IL-12 expression approach, which will be presented at the 2025 ASCO Annual Meeting (May 30–June 3, 2025) in Chicago.

• Phase 3 OVATION 3 Initiation
  The first clinical site for the pivotal Phase 3 OVATION 3 study in newly diagnosed advanced ovarian cancer has been activated, and participant enrollment is underway.

• AACR 2025 Participation (April 25–30, 2025)
  IMUNON scientists and executives attended the American Association for Cancer Research Annual Meeting, focusing on immunotherapy advancements.

• Drug Development & Delivery Feature
  In an industry article, Executive VP and Chief Science Officer Khursheed Nadeem Anwer, Ph.D., MBA, and Chief Medical Officer Douglas V. Faller, MD, Ph.D., discussed IL-12 research and the TheraPlas® platform’s potential in ovarian cancer.

• PlaCCine® Phase 1 Proof-of-Concept
  IMUNON reported immunogenicity, durability, and safety data from its first Phase 1 trial of a DNA plasmid vaccine candidate against SARS-CoV-2, validating the PlaCCine® delivery system.

• Citeline Awards Recognition
  The OVATION 2 study was recognized as a finalist for “Clinical Trial Result of the Year” at the 2025 Citeline Awards in Boston.

SEC Filings

Filing Date	Form Type	Description	Link
May 27, 2025	8-K	Current report: items 1.01, 3.02, 8.01, 9.01
May 22, 2025	8-K	Current report: item 8.01
May 22, 2025	RW	Registration withdrawal request for S-1 No. 333-286403

• Registration Withdrawal (May 22, 2025): IMUNON withdrew its registration statement (S-1 No. 333-286403), indicating no securities were sold and seeking credit toward future filings under Rule 477 of the Securities Act.

Financial and Strategic Analysis

Stock Data (As of May 27, 2025)

Metric	Value
Share Price	$0.8148 (–29.76%)
Volume	1,408,424
52-Week Range	$0.37 – $3.65
Market Capitalization	$20.35 M
Beta (5Y Monthly)	1.75
EPS (TTM)	–$1.38
Net Income (TTM)	–$17.79 M
Total Cash (MRQ)	$2.87 M
Total Debt/Equity (MRQ)	223.01%
Levered Free Cash Flow	–$9.03 M

Pipeline Overview

• IMNN-201 (FixPlas platform): Pre-clinical Trp2 tumor-associated antigen vaccine for melanoma.
• IP-Y (IndiPlas platform): Planned initiation of pre-clinical work on personalized neoepitope cancer vaccines.

Addressable Market: Multiple pipeline candidates targeting oncology and infectious diseases with significant market potential.

Strategic Considerations

• Platform Focus: Emphasis on both immunotherapies (TheraPlas®) and vaccines (PlaCCine®).
• Funding and Liquidity: With $2.87 M in cash and a debt/equity ratio above 200%, capital management will be important.
• Regulatory Pathway: Clinical progress in Phase 2 and Phase 3 oncology trials will drive future milestones.
• Partnerships: Engagements with leading research institutions and interest in strategic collaborations for ongoing and future programs.

Market Position and Industry Context

• IMUNON operates within the biotechnology sector, alongside other clinical-stage oncology and vaccine companies.
• The company’s stock has experienced volatility since the COVID-19 pandemic, with notable declines in valuation (TradingView cited a decline exceeding 99% from its peak).
• The market for DNA-based immunotherapies and vaccines is competitive, with many entities advancing nucleic acid platforms.

tl;dr

• On May 27, 2025, IMUNON’s share price was $0.8148, down 29.76% on significant volume.
• The company filed two Form 8-Ks (May 22 and May 27) and withdrew its public offering registration (May 22).
• Data from the Phase 2 OVATION 2 ovarian cancer study will be presented at ASCO (May 30–June 3, 2025).
• Enrollment has begun for the pivotal Phase 3 OVATION 3 study.
• Pre-clinical programs IMNN-201 and IP-Y are advancing; the PlaCCine® vaccine proof-of-concept data supports further development.
• With limited cash available and high leverage, the company will focus on strategic collaborations and funding to shape its near-term outlook.